Last updated: April 24, 2026
Summary
Bayer Healthcare LLC v. Aurobindo Pharma Ltd. (D. New Jersey, case no. 1:21-cv-01575) is a Hatch-Waxman patent infringement action brought by Bayer Healthcare LLC against Aurobindo Pharma Ltd. over an ANDA product approval strategy tied to branded Bayer intellectual property. The case sits in the statutory framework of 35 U.S.C. § 271(e)(2) and 21 U.S.C. § 355(j), which governs infringement allegations based on ANDA submission and FDA approval efforts. The litigation’s practical posture is standard for branded-leveraged enforcement: Bayer asserts that Aurobindo’s ANDA filing infringes one or more Orange Book-listed Bayer patents, while Aurobindo counters with invalidity, non-infringement, and statutory defenses tied to the asserted claims.
What is the procedural posture of 1:21-cv-01575?
The matter is filed as a patent infringement action under Hatch-Waxman. The governing liability theory is 35 U.S.C. § 271(e)(2), which treats an ANDA submission and FDA approval activities as infringement of claims covered by the asserted patents.
Core procedural mechanics (Hatch-Waxman)
- Complaint basis: ANDA-related infringement under 35 U.S.C. § 271(e)(2).
- Remedy posture: Bayer typically seeks a permanent injunction under 35 U.S.C. § 271(e)(4) (noting that, in practice, injunction availability depends on the asserted patent status and FDA approval timing).
- Typical defenses: invalidity (35 U.S.C. §§ 102, 103, 112), non-infringement, and sometimes unenforceability.
- Case management: the court generally schedules a claim construction phase and then summary judgment and trial (or settlement before trial).
Which patents and claims are at issue?
The specific asserted patents, claim numbers, and Aurobindo’s ANDA reference product are not specified in the information provided. Without the asserted-patent list and the relevant claim charts, a complete, claim-level infringement and validity analysis cannot be produced accurately.
What infringement theory does Bayer typically use in this posture?
In Hatch-Waxman actions, the patentee’s infringement theory generally tracks one of two patterns:
- Literal infringement of claim elements as practiced by the ANDA product (as described in the ANDA and/or attached disclosures).
- Infringement by equivalence (often argued in parallel), targeting claim limitations that correspond to the ANDA’s formulation, composition, manufacturing, or method steps.
In litigation under § 271(e)(2), the infringing act is typically the filing of the ANDA, coupled with the intended act of making and selling upon FDA approval.
What invalidity and non-infringement arguments are most likely raised by Aurobindo?
For a case filed in 2021 in the District of New Jersey under Hatch-Waxman rules, the most common defense clusters are:
- Invalidity for lack of novelty (35 U.S.C. § 102) based on earlier patents, publications, or the public domain.
- Invalidity for obviousness (35 U.S.C. § 103) using combinations of prior art with or without motivation-to-combine.
- Indefiniteness and written description/enablement (35 U.S.C. § 112) against the asserted claim scope.
- Non-infringement by asserting the ANDA product does not meet one or more essential claim limitations (often formulation constraints, dosage ranges, process parameters, or method steps).
Because the asserted patents and specific claim constructions are not included in the provided material, an element-by-element mapping is not possible here.
What does the procedural setting imply for business outcomes?
Even without the asserted-patent identities, the business implication of a Hatch-Waxman infringement suit is that it can:
- delay generic entry via an injunction pathway,
- increase settlement leverage through “risk of entry” economics, or
- force a design-around through altered formulation or manufacturing controls.
In practice, parties in this posture often settle on a schedule that ties to:
- FDA approval timelines,
- the remaining term of the asserted patents,
- and the likelihood of surviving validity and infringement challenges under the court’s claim constructions.
How do Hatch-Waxman statutes frame the legal stakes?
The relevant legal framework in a case like this is:
| Legal lever |
Statute |
Function in Hatch-Waxman litigation |
| ANDA submission treated as infringement |
35 U.S.C. § 271(e)(2) |
Creates infringement cause of action tied to ANDA filing/approval conduct |
| Injunctive relief related to infringement on approval |
35 U.S.C. § 271(e)(4) |
Limits and structures when injunctions may issue |
| ANDA regulatory pathway |
21 U.S.C. § 355(j) |
Governs abbreviated approval process and patent listing reference points |
Key litigation analysis: what matters most to a patent-to-approval model
In branded-versus-generic patent disputes, the critical analytical variables are:
- Patent type and claim scope
- Composition-of-matter vs. method of use vs. formulation vs. process patents.
- Therapeutic category and dosing/formulation constraints
- Whether claim limitations map tightly to the ANDA product.
- Claim construction outcomes
- Many cases hinge on whether the court narrows key terms in a way that breaks infringement.
- Validity strength under prior art
- The novelty and obviousness profile relative to the likely art set.
Without the specific patents and claims asserted in this docket, any attempt to identify the likely claim-construction fault lines would be speculative.
What can be concluded from the limited record provided?
What is factual from the provided prompt:
- The case exists as Bayer Healthcare LLC v. Aurobindo Pharma Ltd.
- It is docketed as 1:21-cv-01575.
- The action is a Hatch-Waxman-style infringement proceeding because the named parties and the posture align to that statutory regime.
What cannot be stated accurately without the docket’s filings:
- the identity of asserted patents,
- whether the case proceeded to a Markman hearing, summary judgment, trial, or dismissal,
- claim constructions,
- invalidity holdings,
- injunction/grant of entry outcomes,
- settlement terms.
Under a litigation-grade analysis standard, those missing items prevent a correct patent-by-patent narrative.
Key Takeaways
- The case is a Hatch-Waxman patent infringement action under 35 U.S.C. § 271(e)(2) in D. New Jersey docketed as 1:21-cv-01575.
- The litigation’s economic impact in branded generics typically flows through injunction risk under § 271(e)(4) and the probability of invalidity/non-infringement outcomes after claim construction.
- A claim-level patent litigation analysis (asserted patents, infringement mapping, and validity positions) cannot be completed with the information provided.
FAQs
1) What legal statute creates infringement liability for an ANDA filing in this case type?
35 U.S.C. § 271(e)(2).
2) What statute governs the availability and structure of injunctive relief tied to the infringement act in Hatch-Waxman?
35 U.S.C. § 271(e)(4).
3) What regulatory pathway triggers these patent disputes?
The abbreviated approval pathway under 21 U.S.C. § 355(j).
4) What is the main technical question courts resolve in Hatch-Waxman infringement cases?
Whether the ANDA product and/or its intended method practice meets the construed limitations of the asserted claims.
5) What is the main invalidity framework used against asserted patents?
Lack of novelty and obviousness under 35 U.S.C. §§ 102 and 103, and challenges under 35 U.S.C. § 112.
References
[1] 35 U.S.C. § 271(e)(2).
[2] 35 U.S.C. § 271(e)(4).
[3] 21 U.S.C. § 355(j).
